Obesity and male breast cancer: provocative parallels?

BMC Medicine

Valerie Speirs²  V. Craig Jordan¹  Matthew P. Humphries² 

[1] Department of Breast Medical Oncology and Molecular and Cellular Oncology, MD Anderson Cancer Center, Houston 77030, TX, USA;Leeds Institute of Cancer and Pathology, University of Leeds, St James’s University Hospital, Leeds LS9 7TF, UK

关键词: Tamoxifen;    Selective estrogen receptor modulator;    Risk factor;    Obesity;    Male breast cancer;    Incidence;    Estrogen;    Body mass index;    Aromatase inhibitor;    Aromatase;   

Others  :  1213734
DOI  :  10.1186/s12916-015-0380-x

 received in 2015-03-03, accepted in 2015-05-19,  发布年份 2015

【 摘 要 】

While rare compared to female breast cancer the incidence of male breast cancer (MBC) has increased in the last few decades. Without comprehensive epidemiological studies, the explanation for the increased incidence of MBC can only be speculated. Nevertheless, one of the most worrying global public health issues is the exponential rise in the number of overweight and obese people, especially in the developed world. Although obesity is not considered an established risk factor for MBC, studies have shown increased incidence among obese individuals. With this observation in mind, this article highlights the correlation between the increased incidence of MBC and the current trends in obesity as a growing problem in the 21^st century, including how this may impact treatment. With MBC becoming more prominent we put forward the notion that, not only is obesity a risk factor for MBC, but that increasing obesity trends are a contributing factor to its increased incidence.

【 授权许可】

   
2015 Humphries et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Tanchou. Statistics of cancer. Lancet. 1843;40:649–50. doi:10.1016/S0140-6736(02)87094-5.
• [2]Ferlay J BF, Steliarova-Foucher E, Forman D. Cancer incidence in five continents, CI5plus: IARC CancerBase No. 9. 2014. http://ci5.iarc.fr. Accessed 19 Dec 2014.
• [3]Cancer facts and figures 2014. American Cancer Society, Atlanta, GA; 2014.
• [4]Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. http://globocan.iarc.fr. Accessed 29 Jul 2014.
• [5]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H et al.. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013; 49:1374-403.
• [6]Ly D, Forman D, Ferlay J, Brinton LA, Cook MB. An international comparison of male and female breast cancer incidence rates. Int J Cancer. 2013; 132:1918-26.
• [7]Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002; 137:678-87.
• [8]Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999; 126:775-80.
• [9]Dabakuyo TS, Dialla O, Gentil J, Poillot ML, Roignot P, Cuisenier J et al.. Breast cancer in men in Cote d’Or (France): epidemiological characteristics, treatments and prognostic factors. Eur J Cancer Care. 2012; 21:809-16.
• [10]White J, Kearins O, Dodwell D, Horgan K, Hanby A, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Res. 2011; 13:219.
• [11]Hodgson NC, Button JH, Franceschi D, Moffat FL, Livingstone AS. Male breast cancer: is the incidence increasing? Ann Surg Oncol. 2004; 11:751-5.
• [12]Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol. 2008; 6:58.
• [13]Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009; 115:429-30.
• [14]Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT et al.. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014; 106:djt465.
• [15]Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G. Breast carcinoma in men: a population-based study. Cancer. 2004; 101:51-7.
• [16]Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004; 83:77-86.
• [17]SEER. Surveillance Epidemiology and End Results (SEER). Program Surveillance Research Program, Surveillance Systems Branch. 2015. NCI. www.seercancer.gov. Accessed 13 Dec 2014.
• [18]Shin JY, Kachnic LA, Hirsch AE. The impact of race in male breast cancer treatment and outcome in the United States: a population-based analysis of 4,279 patients. Int J Breast Cancer. 2014; 2014:685842.
• [19]Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S et al.. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011; 29:4381-6.
• [20]Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013; 119:1611-7.
• [21]O’Malley CD, Prehn AW, Shema SJ, Glaser SL. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002; 94:2836-43.
• [22]Sineshaw HM, Freedman RA, Ward EM, Flanders WD, Jemal A. Black/white disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol. 2015. Ahead of print. doi:10.1200/jco.2014.60.5584.
• [23]CRUK. Breast cancer incidence in males. 2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/uk-breast-cancer-incidence-statistics#source1. Accessed 28 Jan 2015.
• [24]John W. Nick Foundation. Sebastian, FL. 2015. https://www.malebreastcancer.org/. Accessed 14 May 2015.
• [25]Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al.. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384:766-81.
• [26]Roth J, Qiang X, Marban SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obes Res. 2004; 12:88S-101.
• [27]Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML et al.. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011; 378:804-14.
• [28]Annex A. World Health Organization. Obesity and overweight fact sheet. 2011. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 20 Dec 2014.
• [29]Haidar YM, Cosman BC. Obesity epidemiology. Clin Colon Rectal Surg. 2011; 24:205-10.
• [30]De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013; 2013:11.
• [31]AICR. World Cancer Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC. 2nd Edition. http://discovery.ucl.ac.uk/4841/1/4841.pdf. 2007. Accessed 6 Jan 2015.
• [32]Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014; 311:806-14.
• [33]White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Canc Res. 2011; 13:219.
• [34]Shaaban A, Ball G, Brannan R, Cserni G, Di Benedetto A, Dent J et al.. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2012; 133:949-58.
• [35]La Vecchia C, Negri E, Franceschi S, Talamini R, Bruzzi P, Palli D et al.. Body mass index and post-menopausal breast cancer: an age-specific analysis. Br J Cancer. 1997; 75:441-4.
• [36]Trentham-Dietz A, Newcomb PA, Storer BE, Longnecker MP, Baron J, Greenberg ER et al.. Body size and risk of breast cancer. Am J Epidemiol. 1997; 145:1011-9.
• [37]Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al.. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003; 95:1218-26.
• [38]Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J et al.. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20:454-63.
• [39]Monninkhof EM, van der Schouw YT, Peeters PH. Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat. 1999; 55:285-91.
• [40]Scholz C, Andergassen U, Hepp P, Schindlbeck C, Friedl TW, Harbeck N, et al. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer. Breast Cancer Res Treat. 2015. Ahead of print. doi:10.1007/s10549-015-3422-3.
• [41]Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19:1893-907.
• [42]Anderson WF, Devesa SS. Breast carcinoma in men. Cancer. 2005; 103:432-3.
• [43]Misra SP, Misra V, Dwivedi M. Cancer of the breast in a male cirrhotic: is there an association between the two? Am J Gastroenterol. 1996; 91:380-2.
• [44]Guenel P, Cyr D, Sabroe S, Lynge E, Merletti F, Ahrens W et al.. Alcohol drinking may increase risk of breast cancer in men: a European population-based case–control study. Cancer Causes Contro. 2004; 15:571-80.
• [45]Memon MA, Donohue JH. Male breast cancer. Br J Surg. 1997; 84:433-5.
• [46]Alali L, Honarpisheh H, Shaaban A, Speirs V. Conditions of the male breast: gynaecomastia and male breast cancer (Review). Mol Med Rep. 2010; 3:21-6.
• [47]Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenbeck AR et al.. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008; 100:1477-81.
• [48]Cook MB, Guenel P, Gapstur SM, van den Brandt PA, Michels KB, Casagrande JT et al.. Tobacco and alcohol in relation to male breast cancer: an analysis of the male breast cancer pooling project consortium. Cancer Epidemiol Biomarkers Prev. 2015; 24:520-31.
• [49]Bembo SA, Carlson HE. Gynecomastia: its features, and when and how to treat it. Cleve Clin J Med. 2004; 71:511-7.
• [50]Rosen H, Webb ML, DiVasta AD, Greene AK, Weldon CB, Kozakewich H et al.. Adolescent gynecomastia: not only an obesity issue. Ann Plast Surg. 2010; 64:688-90.
• [51]Ersoz H, Onde ME, Terekeci H, Kurtoglu S, Tor H. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia. Int J Androl. 2002; 25:312-6.
• [52]Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer – a case–control study from Scandinavia. Acta Oncologica (Stockholm, Sweden). 2001; 40:467-71.
• [53]Finkelstein JS, O’Dea LS, Whitcomb RW, Crowley WF. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab. 1991; 73:621-8.
• [54]Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000; 85:3027-35.
• [55]Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002; 5:98-102.
• [56]Tchernof A, Mansour MF, Pelletier M, Boulet MM, Nadeau M, Luu-The V. Updated survey of the steroid-converting enzymes in human adipose tissues. J Steroid Biochem Mol Biol. 2015; 147c:56-69.
• [57]Takagi K, Moriya T, Kurosumi M, Oka K, Miki Y, Ebata A et al.. Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma. Horm Cancer. 2013; 4:1-11.
• [58]Speirs V, Green AR, White MC. A comparative study of cytokine gene transcripts in normal and malignant breast tissue and primary cell cultures derived from the same tissue samples. Int J Cancer. 1996; 66:551-6.
• [59]Speirs V, Adams EF, White MC. The anti-estrogen tamoxifen blocks the stimulatory effects of interleukin-6 on 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol. 1993; 46:605-11.
• [60]Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14:189-206.
• [61]Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab. 2007; 3:345-54.
• [62]Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011; 1229:45-52.
• [63]Wang YY, Lehuede C, Laurent V, Dirat B, Dauvillier S, Bochet L et al.. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett. 2012; 324:142-51.
• [64]Cleary MP. Impact of obesity on development and progression of mammary tumors in preclinical models of breast cancer. J Mammary Gland Biol Neoplasia. 2013; 18:333-43.
• [65]Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol. 2015. Ahead of print. doi:10.1200/jco.2014.59.1602.
• [66]Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab. 1979; 48:633-8.
• [67]Kley HK, Edelmann P, Kruskemper HL. Relationship of plasma sex hormones to different parameters of obesity in male subjects. Metabolism. 1980; 29:1041-5.
• [68]Strain GW, Zumoff B, Kream J, Strain JJ, Deucher R, Rosenfeld RS et al.. Mild hypogonadotropic hypogonadism in obese men. Metabolism. 1982; 31:871-5.
• [69]Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014; 16:223-31.
• [70]Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf). 2006; 65:125-31.
• [71]Rohrmann S, Shiels MS, Lopez DS, Rifai N, Nelson WG, Kanarek N et al.. Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Contro. 2011; 22:1141-51.
• [72]Ahn J, Schatzkin A, Lacey JV, Albanes D, Ballard-Barbash R, Adams KF et al.. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007; 167:2091-102.
• [73]Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti IA. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012; 7:e51446.
• [74]Hartz AJ, He T. Cohort study of risk factors for breast cancer in post menopausal women. Epidemiol Health. 2013; 35:e2013003.
• [75]Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006; 367:595-604.
• [76]Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012; 19:3199-204.
• [77]El-Tamer MB, Komenaka IK, Troxel A, Li H, Joseph KA, Ditkoff BA et al.. Men with breast cancer have better disease-specific survival than women. Arch Surg. 2004; 139:1079-82.
• [78]Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL. Body mass and stage of breast cancer at diagnosis. Int J Cancer. 2002; 98:279-83.
• [79]Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008; 111:329-42.
• [80]Haakinson DJ, Leeds SG, Dueck AC, Gray RJ, Wasif N, Stucky CC et al.. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012; 19:3012-8.
• [81]Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient delay and stage of diagnosis among breast cancer patients in Germany – a population based study. Br J Cancer. 2002; 86:1034-40.
• [82]Deglise C, Bouchardy C, Burri M, Usel M, Neyroud-Caspar I, Vlastos G et al.. Impact of obesity on diagnosis and treatment of breast cancer. Breast Cancer Res Treat. 2010; 120:185-93.
• [83]Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014; 21:R235-46.
• [84]Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992; 65:252-4.
• [85]Baojiang L, Tingting L, Gang L, Li Z. Male breast cancer: a retrospective study comparing survival with female breast cancer. Oncol Lett. 2012; 4:642-6.
• [86]Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Psaltopoulou T. Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015; 149:269-75.
• [87]Wenhui Z, Shuo L, Dabei T, Ying P, Zhipeng W, Lei Z et al.. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. Eur J Endocrinol. 2014; 171:527-33.
• [88]Maugeri-Sacca M, Barba M, Vici P, Pizzuti L, Sergi D, De Maria R et al.. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Res Treat. 2014; 147:227-35.
• [89]Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359:2131-9.
• [90]Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003; 98:1802-10.
• [91]Johansson I, Killander F, Linderholm B, Hedenfalk I. Molecular profiling of male breast cancer – Lost in translation? Int J Biochem Cell Biol. 2014; 53:526-35.
• [92]Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ et al.. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2012; 25:398-404.
• [93]Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S et al.. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011; 127:601-10.
• [94]Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J et al.. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat. 2011; 129:747-60.
• [95]Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, Micale L et al.. MicroRNA expression profiling in male and female familial breast cancer. Br J Cancer. 2014; 111:2361-8.
• [96]Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Rohl FW et al.. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013; 137:465-70.
• [97]Bhatnagar AS, Müller P, Schenkel L, Trunet PF, Beh I, Schieweck K. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male. J Steroid Biochem Mol Biol. 1992; 41:437-43.
• [98]Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab. 1993; 77:319-23.
• [99]Mauras N, O’Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000; 85:2370-7.
• [100]Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010; 21:1243-5.
• [101]Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN et al.. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010; 70:319-28.
• [102]Flote VG, Furberg A, McTiernan A, Frydenberg H, Ursin G, Iversen A et al.. Gene variations in oestrogen pathways, CYP19A1, daily 17ss-estradiol and mammographic density phenotypes in premenopausal women. Breast Canc Res. 2014; 16:499.
• [103]Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB et al.. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007; 13:1185-92.
• [104]Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem. 1991; 266:7774-8.
• [105]DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol (Baltimore, Md). 2008; 22:65-77.
• [106]Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS et al.. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013; 5:637-45.
• [107]Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis. 2007; 194:71-8.
• [108]Popkin BM, Adair LS, Ng SW. The global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev. 2012; 70:3-21.
• [109]Darbre PD. Aluminium, antiperspirants and breast cancer. J Inorg Biochem. 2005; 99:1912-9.
• [110]Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS. Concentrations of parabens in human breast tumours. J Appl Toxicol. 2004; 24:5-13.
• [111]Dieterich M, Stubert J, Reimer T, Erickson N, Berling A. Influence of lifestyle factors on breast cancer risk. Breast Care (Basel, Switzerland). 2014; 9:407-14.
• [112]Rodrigues-Peres RM, Cadore S, Febraio S, Heinrich JK, Serra KP, Derchain SF et al.. Aluminum concentrations in central and peripheral areas of malignant breast lesions do not differ from those in normal breast tissues. BMC Cancer. 2013; 13:104.
• [113]Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, et al. Difference in association of obesity with prostate cancer risk between US African American and non-Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015. Ahead of print. doi:10.1001/jamaoncol.2015.0513.
• [114]Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab. 1981; 53:828-32.
• [115]Pellitero S, Olaizola I, Alastrue A, Martinez E, Granada ML, Balibrea JM et al.. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg. 2012; 22:1835-42.
• [116]Blouin K, Veilleux A, Luu-The V, Tchernof A. Androgen metabolism in adipose tissue: recent advances. Mol Cell Endocrinol. 2009; 301:97-103.
• [117]Tomlinson JW, Stewart PM. The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue. Horm. Metab. Res. 2002; 34:746-51.